These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38630996)

  • 1. High-Specific-Activity 131 I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma.
    Al-Ward R; Brondani VB; Sawani S; Potter CL; Xu G; Waguespack SG; Varghese J; Habra MA; Lu Y; Jimenez C
    Clin Nucl Med; 2024 Jul; 49(7):610-620. PubMed ID: 38630996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of High-Specific-Activity
    Pryma DA; Chin BB; Noto RB; Dillon JS; Perkins S; Solnes L; Kostakoglu L; Serafini AN; Pampaloni MH; Jensen J; Armor T; Lin T; White T; Stambler N; Apfel S; DiPippo VA; Mahmood S; Wong V; Jimenez C
    J Nucl Med; 2019 May; 60(5):623-630. PubMed ID: 30291194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma.
    Jimenez C; Chin BB; Noto RB; Dillon JS; Solnes L; Stambler N; DiPippo VA; Pryma DA
    Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36472300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
    Fonte JS; Robles JF; Chen CC; Reynolds J; Whatley M; Ling A; Mercado-Asis LB; Adams KT; Martucci V; Fojo T; Pacak K
    Endocr Relat Cancer; 2012 Feb; 19(1):83-93. PubMed ID: 22167067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
    Gonias S; Goldsby R; Matthay KK; Hawkins R; Price D; Huberty J; Damon L; Linker C; Sznewajs A; Shiboski S; Fitzgerald P
    J Clin Oncol; 2009 Sep; 27(25):4162-8. PubMed ID: 19636009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131 I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma.
    Jimenez C; Lu Y
    Clin Nucl Med; 2023 May; 48(5):426-427. PubMed ID: 36728291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG.
    Thorpe MP; Kane A; Zhu J; Morse MA; Wong T; Borges-Neto S
    J Clin Endocrinol Metab; 2020 Mar; 105(3):e494-501. PubMed ID: 31614368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma.
    Noto RB; Pryma DA; Jensen J; Lin T; Stambler N; Strack T; Wong V; Goldsmith SJ
    J Clin Endocrinol Metab; 2018 Jan; 103(1):213-220. PubMed ID: 29099942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre.
    Rutherford MA; Rankin AJ; Yates TM; Mark PB; Perry CG; Reed NS; Freel EM
    QJM; 2015 May; 108(5):361-8. PubMed ID: 25267727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma.
    Gedik GK; Hoefnagel CA; Bais E; Olmos RA
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):725-33. PubMed ID: 18071700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma.
    Wakabayashi H; Taki J; Inaki A; Nakamura A; Kayano D; Fukuoka M; Matsuo S; Nakajima K; Kinuya S
    Ann Nucl Med; 2013 Nov; 27(9):839-46. PubMed ID: 23864328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma.
    Rose B; Matthay KK; Price D; Huberty J; Klencke B; Norton JA; Fitzgerald PA
    Cancer; 2003 Jul; 98(2):239-48. PubMed ID: 12872341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
    Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
    J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Specific-Activity-
    Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
    Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [
    Prado-Wohlwend S; Del Olmo-García MI; Bello-Arques P; Merino-Torres JF
    Front Endocrinol (Lausanne); 2022; 13():778322. PubMed ID: 35197929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [
    Inaki A; Shiga T; Tsushima Y; Jinguji M; Wakabayashi H; Kayano D; Akatani N; Yamase T; Kunita Y; Watanabe S; Hiromasa T; Mori H; Hirata K; Watanabe S; Higuchi T; Tomonaga H; Kinuya S
    Ann Nucl Med; 2022 Mar; 36(3):267-278. PubMed ID: 34870794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 131-I MIBG therapy of malignant pheochromocytoma and paraganglioma tumours - a single-centre study.
    Kotecka-Blicharz A; Hasse-Lazar K; Handkiewicz-Junak D; Gawlik T; Pawlaczek A; Oczko-Wojciechowska M; Michalik B; Szpak-Ulczok S; Krajewska J; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2018; 69(3):246-251. PubMed ID: 29645065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I clinical trial for [
    Wakabayashi H; Inaki A; Yoshimura K; Murayama T; Imai Y; Higuchi T; Jinguji M; Shiga T; Kinuya S
    Sci Rep; 2019 May; 9(1):7625. PubMed ID: 31110198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.